- Home
- BCAX vs BCSF Comparison
BCAX vs BCSF Comparison
Compare BCAX & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAX
- BCSF
- Stock Information
- Founded
- BCAX 2018
- BCSF 2015
- Country
- BCAX United States
- BCSF United States
- Employees
- BCAX N/A
- BCSF N/A
- Industry
- BCAX
- BCSF Finance/Investors Services
- Sector
- BCAX
- BCSF Finance
- Exchange
- BCAX NYSE
- BCSF Nasdaq
- Market Cap
- BCAX 1.0B
- BCSF 1.1B
- IPO Year
- BCAX 2024
- BCSF 2018
- Fundamental
- Price
- BCAX $12.11
- BCSF $17.36
- Analyst Decision
- BCAX Strong Buy
- BCSF Hold
- Analyst Count
- BCAX 5
- BCSF 4
- Target Price
- BCAX $41.33
- BCSF $16.75
- AVG Volume (30 Days)
- BCAX 603.8K
- BCSF 194.2K
- Earning Date
- BCAX 02-16-2025
- BCSF 02-25-2025
- Dividend Yield
- BCAX N/A
- BCSF 10.35%
- EPS Growth
- BCAX N/A
- BCSF N/A
- EPS
- BCAX N/A
- BCSF 1.99
- Revenue
- BCAX N/A
- BCSF $294,257,000.00
- Revenue This Year
- BCAX N/A
- BCSF N/A
- Revenue Next Year
- BCAX N/A
- BCSF N/A
- P/E Ratio
- BCAX N/A
- BCSF $8.75
- Revenue Growth
- BCAX N/A
- BCSF 3.17
- 52 Week Low
- BCAX $11.56
- BCSF $14.78
- 52 Week High
- BCAX $28.09
- BCSF $17.97
- Technical
- Relative Strength Index (RSI)
- BCAX N/A
- BCSF 53.36
- Support Level
- BCAX N/A
- BCSF $16.79
- Resistance Level
- BCAX N/A
- BCSF $17.58
- Average True Range (ATR)
- BCAX 0.00
- BCSF 0.27
- MACD
- BCAX 0.00
- BCSF -0.02
- Stochastic Oscillator
- BCAX 0.00
- BCSF 48.31
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes, First Lien Senior Secured Loan, Preferred Equity, Equity Interest, and Second Lien Senior Secured Loan among others.